Walgreens Boots Alliance, Inc. (WBA) and Postmates said they would collaborate on delivery for customers.
With the collaboration, Postmates will deliver health and wellness,
beauty and grocery products from 174 Walgreens and Duane Reade locations
in Manhattan and Brooklyn.
“In the last year, orders from convenience and drugstores have
increased by 68%. By collaborating with Walgreens, we are able to
provide our customers with even more convenience when it comes to
everyday items that they need now,” said Craig Whitmer, vice president
of merchant business development for Postmates.
To order items from participating Walgreens stores, users can go to the Postmates website or download the Postmates app.
https://www.marketscreener.com/WALGREENS-BOOTS-ALLIANCE-19356230/news/Walgreens-Boots-Alliance-Postmates-To-Collaborate-on-Delivery-in-Manhattan-and-Brooklyn-29325737/
Wednesday, October 2, 2019
Wedbush: Investors Largely Underappreciating AnaptysBio
AnaptysBio Inc ANAB
released topline results Monday from an interim data analysis from a
midstage study of its investigational asset ANAB019, which being
evaluated for moderate-to-severe generalized pustular psoriasis.
Compared to Boehringer Ingelheim’s IL-36R inhibitor B1655130, the
analyst said he sees the potential for NB019 to become the
best-in-the-class antagonist.
With B1655130, anti-drug antibodies were observed in three patients, whichmay limit prolonged and multiple dosing, he said.
With ANB019, neither of the two patients in the study required rescue therapy during the treatment period, Nierengarten said; one patient treated with B1655130 required rescue therapy.
Despite the different efficacy scales used in the two studies that rendered the data incomparable, ANB019’s lack of observed anti-drug antibodies represents a key potential differentiator relative to B1655130, the analyst said.
AnaptysBio plans to continue enroll patients in the midstage study, with an enrollment target of 10 patients, he said.
The company is expected to give a data and development update for the program later in 2020, Nierengarten said.
The analyst sees the data as having a positive read-through to the Phase 2 POPLAR study that is evaluating ANB019 in an inflammatory skin condition, palmoplantar pustulosis.
“As such, with interim Ph 2 GPP data de-risking the asset and multiple data readouts for ANB019 expected over the next 12 months, we believe that investors are largely underappreciating ANAB’s second clinical candidate (and ANAB shares in general).”
The upcoming topline Phase 2b ATLAS study readout for AnaptysBio’s lead candidate etokimab in atopic dermatitis and the topline Phase 2 ECLIPSE readout in chronic rhinosinusitis with nasal polyps in the fourth quarter of 2019 could serve as the next major drivers of share value, according to Wedbush.
https://www.benzinga.com/analyst-ratings/analyst-color/19/10/14522016/wedbush-investors-largely-underappreciating-anaptysbio
The Analyst
Wedbush analyst David Nierengarten reiterated an Outperform rating on AnaptysBio with a $146 price targetThe Thesis
Overall, new data from the study showed highly compelling efficacy, with rapid and sustained reductions in relevant disease metrics from the initial day eight assessment to the day 113 assessment, Nierengarten said in a Tuesday note.With B1655130, anti-drug antibodies were observed in three patients, whichmay limit prolonged and multiple dosing, he said.
With ANB019, neither of the two patients in the study required rescue therapy during the treatment period, Nierengarten said; one patient treated with B1655130 required rescue therapy.
Despite the different efficacy scales used in the two studies that rendered the data incomparable, ANB019’s lack of observed anti-drug antibodies represents a key potential differentiator relative to B1655130, the analyst said.
AnaptysBio plans to continue enroll patients in the midstage study, with an enrollment target of 10 patients, he said.
The company is expected to give a data and development update for the program later in 2020, Nierengarten said.
The analyst sees the data as having a positive read-through to the Phase 2 POPLAR study that is evaluating ANB019 in an inflammatory skin condition, palmoplantar pustulosis.
“As such, with interim Ph 2 GPP data de-risking the asset and multiple data readouts for ANB019 expected over the next 12 months, we believe that investors are largely underappreciating ANAB’s second clinical candidate (and ANAB shares in general).”
The upcoming topline Phase 2b ATLAS study readout for AnaptysBio’s lead candidate etokimab in atopic dermatitis and the topline Phase 2 ECLIPSE readout in chronic rhinosinusitis with nasal polyps in the fourth quarter of 2019 could serve as the next major drivers of share value, according to Wedbush.
https://www.benzinga.com/analyst-ratings/analyst-color/19/10/14522016/wedbush-investors-largely-underappreciating-anaptysbio
ArQule launches registrational study of miransertib in PS and PROS
ArQule (NASDAQ:ARQL) doses
first patient in the registrational MOSAIC (Miransertib in Overgrowth
Syndromes in Adults and Children) trial of its oral, selective pan-AKT
inhibitor, miransertib, for the treatment of Proteus syndrome (PS) and
PIK3CA-related Overgrowth Spectrum disorders (PROS).
The study will enroll approx. 30-35 patients to
evaluate the objective response to miransertib in patients with PS and
PROS. Same number of patients will be enrolled in 2 other cohorts for
patients under compassionate use or those ineligible to enter the
registrational cohorts.
https://seekingalpha.com/news/3503283-arqule-launches-registrational-study-miransertib-ps-prosRa Pharmaceuticals launches late-stage zilucoplan trial for gMG
Ra Pharmaceuticals (NASDAQ:RARX) initiates
dosing in the RAISE study, its pivotal, Phase 3 clinical trial
evaluating zilucoplan for the treatment of generalized myasthenia gravis
(gMG).
The trial is expected to enroll approx. 130 patients.
The primary endpoint is the change in the MG
Activities of Daily Living (MG-ADL) score from baseline to week 12.
Top-line results are expected in early 2021.
https://seekingalpha.com/news/3503286-ra-pharmaceuticals-launches-late-stage-zilucoplan-trial-gmgFDA accepts Merck’s two applications for Dificid
The FDA accepts for review Merck’s (NYSE:MRK)
NDA for DIFICID (fidaxomicin) for oral suspension, and a supplemental
NDA (sNDA) for a new indication for use of DIFICID tablets and oral
suspension for the treatment of Clostridium (also known as
Clostridioides) difficile infections in children aged six months or
older.
Under Priority Review Status, the agency’s action date is January 24, 2020, for both the applications.
https://seekingalpha.com/news/3503248-fda-accepts-mercks-two-applications-dificidMerck Keytruda approved as lung cancer monotherapy in China
The National Medical Products Administration in China approves Merck’s (NYSE:MRK) KEYTRUDA as
monotherapy for the first-line treatment of patients with locally
advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors
express PD-L1, with no EGFR or ALK genomic tumor aberrations.
KEYTRUDA is now the first anti-PD-1 therapy
approved in China as both monotherapy and in combination with
chemotherapy for the first-line treatment of patients with NSCLC.
https://seekingalpha.com/news/3503255-merck-s-keytruda-approved-monotherapy-china-patients-nsclcLantheus Holdings to buy Progenics
Lantheus Holdings (NASDAQ:LNTH) agrees to acquire Progenics (NASDAQ:PGNX)
in an all-stock transaction, adding targeted medicines and artificial
intelligence to find, fight, an follow cancer to its portfolio.
Progenics shareholders will get 0.2502 shares of
Lantheus Holdings stock for each share of PGNX; implies a 21.5% premium
to Progenics’ 30-day volume weighted average closing stock price.
The two companies had pro forma combined revenue of $370.1M for the 12 months ended June 30, 2019.
“With this combination, we broaden our reach in
emerging uses of radioisotopes for precision diagnostics and the
exciting and expanding field of radiopharmaceuticals in oncology
treatment,” said Lantheus President and CEO Mary Anne Heino.
Deal is expected to close in Q1 2020.
https://seekingalpha.com/news/3503256-lantheus-holdings-buy-progenics
Subscribe to:
Posts (Atom)